iBio (IBIO) investor relations material

Strategic focus and industry landscape

• Emphasis on long-acting antibodies for obesity, targeting cardiometabolic and cardiopulmonary diseases, with a focus on quality and durability of weight loss beyond GLP-1s.

• Pipeline includes fat-selective weight loss, muscle preservation, pulmonary hypertension, heart failure, and amylin programs.

• Market expected to hypersegment, with combination therapies likely to dominate obesity treatment, addressing underlying pathologies rather than cosmetic weight loss.

• Durability of weight loss and adverse effect management are key unmet needs, with current therapies showing limitations in long-term efficacy and tolerability.

• Quality of weight loss, particularly reduction of visceral fat and muscle preservation, is seen as critical for long-term health outcomes.

Pipeline innovation and technology platform

• Lead asset IBIO-610 targets Activin E, a genetically validated pathway for metabolic and cardiovascular disease protection, with a unique antibody developed using proprietary screening technologies.

• Only company with an Activin E antibody, offering potential for complete pathway blockade and superior efficacy compared to siRNA approaches.

• Long-acting antibody design enables dosing intervals of three to six months, with estimated human half-life of 50–100 days.

• Amylin program includes four molecules targeting different receptor subtypes, aiming to optimize efficacy and minimize adverse effects through selective antibody development.

• AI and advanced antigen/antibody discovery technologies enable rapid and precise molecule development, distinguishing the platform from typical AI drug discovery companies.

Clinical development and operational strategy

• Transitioned to clinical stage with IBIO-600, a myostatin-targeting molecule for muscle preservation, now fully dosed in single ascending dose (SAD) cohorts.

• Building an integrated, lean clinical development team led by a new Chief Medical Officer with end-to-end experience, focusing on advancing assets to end of phase II.

• Early clinical studies prioritize safety, pharmacokinetics, and biomarker-driven assessment of efficacy, particularly using imaging to track visceral fat and muscle mass changes.

• Strategic goal is to create valuable clinical assets for partnership or further funding, with phase III trials considered a future objective.